Ref no. | Sx | M/F | Age | Mediators | Index T | Cont T | Site sp | Rnd | Mal | N drug H | N bone Ls | N Ging inflm | PD (<2Â mm) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
22 | 16 | 2 M, 14 F | 18 to 24 y | IL-1β | Mx and Md C | Md R or L C | D | Y | Class I biMx | Y | NM | Y | NM |
23 | 22 | 11 M, 11 F | 14.4 + _1.1 y | Leptin | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
24 | 33 | 21 M, 12 F | 10.8 to 30.9 y | IL-1β, IL-1RA | Mx C | IP Md C/Aj T | D | y | Mx 1st PM Extr cs | NM | NM | NM | NM |
25 | 12 | 7Â F, 5Â M | 13 to 17 y | OPG | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
26 | 9 | 5 M, 4 M | 10 to 18 y | IL-1β, βG | 1st Mo, 1st PM, CI | NM | MP and MB | N | RME cs | NM | NM | NM | NM |
27 | 12 SD (6) LD (6) | SD: 3 M, 3 F LD-NM | SD: 11 to 18 y LD: 19 to 27 y | IL-1β, −6, IL-8, TNF-α | Mx 1st PM | Ant T | DB | N | Mx 2nd PM Extr cs | Y | Y | Y | Y |
28 | 10 | 4 M, 6 F | NM | TNF-α | C | NM | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
29 | 18 | 9 M, 9 F | 16 to 19 y | IL-1β, −TNF-α | Mx C | NM | M and D | N | 1st PM Extr cs | Y | Y | Y | Y |
30 | 30:15 J/15 A | J: 7 M, 9 F A: 6 M, 9 F | J: 15.1 ± 2.8 y | RANKL, OPG | 1 Mx C | Contr and ant C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
A: 31 ± 3.6 y | |||||||||||||
31 | 15 | 6Â M, 9Â F | 15 to 19 y | IL-2, IL-6, IL-8 | Mx C | NM | M and D | N | 1st PM Extr cs | Y | Y | Y | Y |
32 | 10 | 4 M, 6 F | M −14.5 y | RANKL, OPG | Mx C | Contr and opposing C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
F 15.4 y | |||||||||||||
33 | 18 | 10 M, 8 F | 8.9 to 13.8 y | IL-1β, SP, PGE2 | 1st Mx/Md M | Ant L or R 1st M | DB and DP | N | Crowding in 1 or both jaws | Y | Y | Y | Y |
34 | 9 | 3 M, 6 F | M: 21.3 ± 2.8 y | IL-1β, SP | Mx C | Contr C | D | N | Mx 1st PM Extr cs | Y | Y | Y | Y |
F: 23.1 ± 2.4 y | |||||||||||||
35 | 10 | 3 M, 7 F | 10 y 5 m to 30 y 11 m | IL-1β, IL-1RA | R and L Mx C | Md. R C | M and D | Y | Mx 1st PM Extr cs | NM | NM | NM | NM |
36 | 10 | NM | 15 to 17 y | IL-8 | Mx and Md C | NM | M and D | Â | 1st PM Extr cs | Y | Y | Y | Y |
37 | 10 | 2 M, 8 F | 18.4 to 22.5 y | IL-1β, PGE2 | Mx C (E1), Contr Mx C (E2) | Ant Md C | D | N | All 1st PM Extr cs | Y | Y | Y | Y |
38 | 84 | 43 J (M) | J: 11 ± 0.7 y | PGE-2, IL-6, GMCSF | Mx LI | Contr LI | M and DB | N | Labial tipping reqd | Y | Y | Y | Y |
41 A (M) | A: −24 ± 1.6 y | ||||||||||||
39 | 9 | 5 M, 4 F | 10 to 18 y | IL-1β βG | 1st Mo, 1st PM, CI | NM | MP and MB | N | RME cs | Y | Y | Y | Y |
40 | 7 | 2 M, 5 F | 12 y 3 m to 16 y 3 m | IL-1β, IL-1RA, AI | Mx C | Md C | M and D | NM | All 1st PM Extr | Y | NM | Y | NM |
41 | 12 | 3 M, 9 F | 14.4 ± 0.9 y | TGF-β | C | Ant C/Contr C | D | NM | All 1st PM Extr | Y | Y | Y | Y |
42 | 12 | 3 M, 9 F | 14.4 ± 0.9 y | IL-1β, IL-6, TNF-α, EGF, β2-μG | C | Ant C/Contr C | D | NM | All 1st PM Extr | Y | Y | Y | Y |
19 | 10 | 5 M, 5 F | M: 24.6 ± 1.5 y F: 27.8 ± 3.9 y | IL-1β, PGE | Mx LI, Mx 1st PM | Contr T | MB | N | Buccal/labial OTM | Y | Y | Y | Y |
43 | 50 | 23 M, 27 F | 13 to 20 y | IL-1β, TNF-α, NO | Mx I, Mx C | NM | M and D | NM | Non Extr | Y | NM | Y | Y |
44 | 10 | 5Â M, 5Â F | 12 to 16 y | RANKL, OPG | 1st PM (quad 1) | 1st PM (quad 2) | D | NM | 2nd Mx PM Extr | Y | NM | Y | NM |
45 | 22 | 7Â M, 15Â F | 19 to 29 y | HSP70, RANKL | Mx C | Contr C | Â | NM | Mx 1st PM Extr | Y | NM | Y | NM |
46 | 12 | 6 M, 6 F | 11 to 15 y | MMP-8, IL-1β | 1st M, CI, C | NM | M | NM | NM | Y | Y | Y | Y |
47 | 21 | NM | 12 to 20 y | GM-CSF, IF-ϒ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNFα, MMP-9, TIMP-1 and 2, RANKL, OPG | Mx C | 2nd M | MB and DP | NM | Mx 1st PM Extr | Y | Y | Y | Y |
48 | 10 | 5 M, 5 F | 22 to 29 y | RANK, OPG, OPN, TGF-β1 | 1st M | Contr M | Exp T: MB and DB Cont T: MB and ML | Y | NM | Y | NM | Y | Y |
49 | 14 | 3 M, 11 F | 12 to 28 y | MMP-3, MMP-9, MMP-13, MIP-1β, MCP-1, RANTES | Mx C | NM | M and D | NM | Mx 1st PM Extr | Y | NM | NM | NM |
50 | 18 | 8 M, 10 F | 8.9 to 13.8 y | IL-1β, SP, PGE2 | 1st M | Contr M | M and D | NM | Crowding in Mx and Md | Y | Y | Y | Y |
51 | 10 | NM | 16.3 ± 2.5 y | IL-1β | Mx C | Md C | DB | NM | Class II, all 1st PM Extr | Y | Y | Y | Y |
52 | 16 | 8 M, 8 F | 16.6 ± 2.4 y | IL-2, IL-6, IL-8 | Mx C | Mx 2nd PM | DB | NM | Mx 1st PM Extr | Y | Y | Y | Y |
53 | 20 | C: 3 M, 7 F EX:5M,5 F | 18 to 45 y | CCL-2 (MCP1), CCL-3, CCL-5 (RANTES), IL-8 (CXCL8), IL-1α, IL-1β, IL-6, TNF-α | Mx C | Contr C | DB | Y | Class II Div 1 Mal With 1st PM Extr | Y | Y | Y | Y |
54 | 16 | 8 M, 8 F | 16.6 ± 2.4 y | TNF-α | Mx C | Mx 2nd PM | DB | NM | Mx 1st PM Extr | Y | Y | Y | Y |
55 | 17 | 9 M, 8 F | 16 to 20 y | TNF-α, IL-1β, IL-8 | Mx C | NM | M and D | NM | All 1st PM Extr | Y | Y | Y | Y |
56 | 10 | 5 M, 5 F | 15 y ± 3 y 8 m | IL-1β, IL-1RA | Mx C | Md C/Aj t | D | NM | All 1st PM Extr | NM | NM | NM | NM |
57 | 20 | 10 ado (3 M, 7 F), 10 A (4 M, 6 F) | Ado: 14.4 ± 1.43 y A: −28.5 ± 7.83 y | RANKL, OPG, IL-1, IL-1RA, MMP-9 | Mx I | Md I | Lab | NM | Non Extr, 3 to 6 mm I crowding | N | N | Y | N |
58 | 24 HG-14 NHG-10 | 10 M, 14 F HG: 6 M, 8 F | 14.66 ± 1.1 y | IL-2, IL-4, IL-6, IL-8, IL-10, GM-CSF, IFN-γ, TNFα, MCP-1, IP-10 | Mx 1st M and Mx 1st PM | NM | MB and DB | N | Non extr cs | Y | NM | Y | Y |
59 | 9 | 4Â M, 5Â F | 17.5 to 18.9Â y | OPG, RANKL | Mx C | NM | M and D | NM | All 4 Extr | Y | Y | Y | Y |